Dr. Jennifer F. Carney

Hematology Oncology | Hematology | Oncology
Kaiser Permanente
Kaiser Permanente Moanalua Medical Center
3288 Moanalua Rd, 
Honolulu, HI 
Accepting New Patients
Kaiser Permanente
Kaiser Permanente Moanalua Medical Center
3288 Moanalua Rd, 
Honolulu, HI 

Overview

Jennifer Carney is a Hematologist Oncology specialist and a Hematologist practicing medicine in Honolulu, Hawaii.

Her clinical expertise encompasses Breast Cancer, Hajdu-Cheney Syndrome, Angiosarcoma, and Inflammatory Breast Cancer.

She is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 16 clinical trials. Dr. Carney is currently accepting new patients.

Graduate Institution

North Carolina Medical School

Specialties

Hematology Oncology
Hematology
Oncology

Licenses

Internal Medicine in HI

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

HMSA
  • HMO
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Kaiser Permanente Moanalua Medical Center
3288 Moanalua Rd, Honolulu, HI 96819

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Enrollment Status: Active_not_recruiting
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Pertuzumab
Study Phase: Phase 3
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 2
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Metformin, Dapagliflozin
Study Phase: Phase 2
LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Unknown
Publish Date: March 09, 2023
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

3 Total Publications

Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non-Small Cell Lung Cancer (LIQUIK).
Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non-Small Cell Lung Cancer (LIQUIK).
Journal: JCO precision oncology
Published: June 26, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Fariba Navid
Hematology | Oncology
Expertise in
13
conditions
Dr. Fariba Navid
Hematology | Oncology

Children's Hospital Los Angeles

550 S Beretania St Ste 201, 
Honolulu, HI 
 (4.8 miles away)
323-660-2450
Languages Spoken:
English
See accepted insurances

Fariba Navid is a Hematologist and an Oncologist practicing medicine in Honolulu, Hawaii. Dr. Navid is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Neuroblastoma, and Bone Marrow Aspiration.

Expertise in
16
conditions
Dr. Rachna Anand
Hematology Oncology | Hematology | Oncology
Expertise in
16
conditions
Dr. Rachna Anand
Hematology Oncology | Hematology | Oncology

Kapiolani Medical Center For Women & Children

1319 Punahou Street, Suite 640, 
Honolulu, HI 
 (6.1 miles away)
808-983-6090
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rachna Anand is a Hematologist Oncology specialist and a Hematologist practicing medicine in Honolulu, Hawaii. Dr. Anand is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Sideroblastic Anemia, Inflammatory Breast Cancer, Angiosarcoma, and Autoimmune Hemolytic Anemia. Dr. Anand is currently accepting new patients.

Expertise in
29
conditions
Dr. C G. Choy
Hematology Oncology | Hematology
Expertise in
29
conditions
Dr. C G. Choy
Hematology Oncology | Hematology

Pali Momi Medical Center

98-1005 Moanalua Road, Suite 4030, 
Aiea, HI 
 (3.1 miles away)
808-485-3037
Languages Spoken:
English
See accepted insurances
Offers Telehealth

C Choy is a Hematologist Oncology specialist and a Hematologist practicing medicine in Aiea, Hawaii. Dr. Choy is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Jennifer F. Carney

How do I make an appointment with Dr. Jennifer F. Carney?

You can book an appointment with Dr. Jennifer F. Carney by calling their office at 808-432-0000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jennifer F. Carney a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer F. Carney is classified as an Experienced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jennifer F. Carney specialize in?

While Dr. Jennifer F. Carney is a Hematology Oncology, they have specific expertise in Breast Cancer, Hajdu-Cheney Syndrome, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Jennifer F. Carney participate in research or clinical trials?

Yes. Dr. Jennifer F. Carney has published 3 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Jennifer F. Carney's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jennifer F. Carney accept my insurance?

Dr. Jennifer F. Carney accepts most major insurance plans, including HMSA and Kaiser. We recommend calling the office directly at 808-432-0000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carney's expertise for a condition
ConditionClose
        View All 11 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile